Publication:
MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.

Simple item page
dc.contributor.authorSan José-Enériz, Edurne
dc.contributor.authorRomán-Gómez, José
dc.contributor.authorJiménez-Velasco, Antonio
dc.contributor.authorGarate, Leire
dc.contributor.authorMartin, Vanesa
dc.contributor.authorCordeu, Lucia
dc.contributor.authorVilas-Zornoza, Amaia
dc.contributor.authorRodríguez-Otero, Paula
dc.contributor.authorCalasanz, María José
dc.contributor.authorPrósper, Felipe
dc.contributor.authorAgirre, Xabier
dc.contributor.authoraffiliation[San José-Enériz,E; Garate,L; Cordeu,L; Vilas-Zornoza,A; Rodríguez-Otero,P; Prósper,F; Aguirre,X] Foundation for Applied Medical Research, Division of Cancer, Area of Cell Therapy and Hematology Service, Clínica Universitaria, Universidad de Navarra, Spain. [Román-Gómez, J; Martin,V] Department of Hematology. Hospital Reina Sofía e Instituto Maimónides de Investigación Biomédica, Córdoba, Spain. [Jiménez-Velasco,A] Department of Hematology, Hospital Carlos Haya, Málaga, Spain. [Calasanz,MJ] Department of Genetics, University of Navarra, Spain.es
dc.contributor.funderSupported by grants from Beca Ortiz de Landázuri 2006, Departamento de Salud-Gobierno de Navarra; Fondo de Investigación Sanitaria (FIS, Spain), PI070602, PI070608, PI060003, CP07/00215 and RD06/0020; Junta de Andalucía 0386/2006 and 0004/2007; Asociación Medicina e Investigación (AMI) and "UTE project CIMA".
dc.date.accessioned2013-07-10T11:12:36Z
dc.date.available2013-07-10T11:12:36Z
dc.date.issued2009-09-01
dc.descriptionAdditional file 1 Expression of 250 miRNAs in resistant and responder CML patients. The data provided represent the expression of microRNA.es
dc.description.abstractThe development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML. In this study, we have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML.es
dc.description.versionYeses
dc.identifier.citationSan José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol. Cancer. 2009; 8:69es
dc.identifier.doi10.1186/1476-4598-8-69
dc.identifier.essn1476-4598
dc.identifier.pmcPMC2743636
dc.identifier.pmid19723306
dc.identifier.urihttp://hdl.handle.net/10668/1209
dc.journal.titleMolecular cancer
dc.language.isoen
dc.publisherBioMed Centrales
dc.relation.publisherversionhttp://www.molecular-cancer.com/content/8/1/69/abstractes
dc.rights.accessRightsopen access
dc.subjectAntineoplásicoses
dc.subjectAnálisis de clusteres
dc.subjectResistencia a antineoplásicoses
dc.subjectLeucemia mielogenosa crónica BCR-ABL positivaes
dc.subjectMicroARNes
dc.subjectPirimidinases
dc.subjectReacción en cadena de la polimerasa de transcriptasa inversaes
dc.subjectPerfiles de expresión génicaes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agentses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Cluster Analysises
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasmes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Gene Expression Profilinges
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positivees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Antisense::MicroRNAses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Piperazineses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Nucleic Acid Amplification Techniques::Polymerase Chain Reaction::Reverse Transcriptase Polymerase Chain Reactiones
dc.titleMicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.es
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
SanJoseEneriz_MicroRNAExpression.pdf
Size:
783.34 KB
Format:
Adobe Portable Document Format
Description:
Articulo publicado
Download
Thumbnail Image
Name:
SanJoseEneriz_AdditionalMaterial.pdf
Size:
32.29 KB
Format:
Adobe Portable Document Format
Description:
Tablas
Download

Collections

SAS - Hospital Universitario Reina Sofía
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - Hospital Regional Universitario de Málaga

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía